Copenhagen, Denmark
Onsite/Online

ESTRO 2022

Session Item

Breast
6006
Poster (digital)
Clinical
CBCT review confirm reproducible DIBH with AlignRT InBore
Daniel NGUYEN, France
PO-1198

Abstract

CBCT review confirm reproducible DIBH with AlignRT InBore
Authors:

Daniel NGUYEN1, Fabrice Lorchel1, Adel Mamou2, Nicolas Barbet1, Isabelle Pouchard1, François Renoult1, Jad Farah3, Mustapha Khodri1

1Centre de radiothérapie de Mâcon, Saône et loire, Mâcon, France; 2Neural, Hérault, Montpelier, France; 3Vision RT, London, London, United Kingdom

Show Affiliations
Purpose or Objective

To investigate the reproducibility of deep-inspiration breath hold (DIBH) breast cancer treatments on Halcyon™ performed using the first clinical version of AlignRT InBore™.

Material and Methods

The ease and feasibility of DIBH treatments was retrospectively investigated for the initial 22 left breast cancer patients treated on Halcyon™ using the first clinical version of AlignRT InBore™. Setup time, CBCT imaging and analysis time as well as overall treatment time were recorded. Online and offline review of CBCT images was undertaken to verify the compliance of breast, heart, spine, sternum and lung domes positions. 

Results

Mean ± standard deviation for patient setup, CBCT analysis and overall treatment time were 4 ± 0.6 min, 1.1 ± 0.2 min and 14 ± 1.8 min respectively. Online review of 520 CBCT acquisitions showed minimal positioning shifts with AlignRT InBore™ guidance with mean ± standard deviation of vertical, longitudinal, and lateral shifts of 1.7 ± 2.5 mm, -1.7 ± 3.8 mm, and -0.2 ± 2.5 mm respectively. Meanwhile, offline review of 115 CBCTs, showed reproducible BH with average ± standard magnitude deviation of breast, heart, spine, sternum and lung domes within 2.3 ± 2.4 mm, 2.9 ± 2.0 mm, 3.3 ± 2.2 mm, 3.2 ± 2.4 mm and 5.0 ± 6.7 mm respectively. 

Conclusion

AlignRT InBore™ allows for accurate and reproducible DIBH on Halcyon™ with breast and heart organs’ positions within 3 mm (in magnitude) of expected position and fully compliant with local clinical and dosimetry margins.